20 research outputs found
Recommended from our members
Iodinated Contrast Opacification Gradients in Normal Coronary Arteries Imaged With Prospectively ECG-Gated Single Heart Beat 320-Detector Row Computed Tomography
Background
To define and evaluate coronary contrast opacification gradients using prospectively ECG-gated single heart beat 320-detector row coronary angiography (CTA).
Methods and Results
Thirty-six patients with normal coronary arteries determined by 320 × 0.5 mm detector row coronary CTA were retrospectively evaluated with customized image post-processing software to measure Hounsfield Units (HU) at 1 mm intervals orthogonal to the artery center line. Linear regression determined correlation between mean HU and distance from the coronary ostium (regression slope defined as the distance gradient Gd), lumen cross-sectional area (Ga), and lumen short axis diameter (Gs). For each gradient, differences between the three coronary arteries were analyzed with ANOVA. Linear regression determined correlations between measured gradients, heart rate, body-mass index (BMI), and cardiac phase. To determine feasibility in lesions, all three gradients were evaluated in 22 consecutive patients with left anterior descending artery lesions greater than or equal to 50% stenosis. For all 3 coronary arteries in all patients, the gradients Ga and Gs were significantly different from zero (p0.503). The distance gradient Gd demonstrated nonlinearities in a small number of vessels and was significantly smaller in the RCA when compared to the left coronary system (p<0.001). Gradient variations between cardiac phases, heart rates, BMI, and readers were low. Gradients in patients with lesions were significantly different (p<0.021) than in patients considered normal by CTA.
Conclusions
Measurement of contrast opacification gradients from temporally uniform coronary CTA demonstrates feasibility and reproducibility in patients with normal coronary arteries. For all patients the gradients defined with respect to the coronary lumen cross-sectional area and short axis diameters are highly linear, not significantly influenced by the coronary artery (LAD vs LCx vs RCA), and have only small variation with respect to patient parameters. Preliminary evaluation of gradients across coronary artery lesions is promising but requires additional study
Diagnostic accuracy of semi-automatic quantitative metrics as an alternative to expert reading of CT myocardial perfusion in the CORE320 study
Cardiolog
Safety and cardiovascular efficacy of spironolactone in dialysis-dependent ESRD (SPin-D): a randomized, placebo-controlled, multiple dosage trial.
Safety and Cardiovascular Efficacy of Spironolactone in Dialysis-Dependent ESRD (SPin-D): A Randomized, Placebo-Controlled, Multiple Dosage Trial.
Comprehensive Assessment of Radiation Dose Estimates for the CORE320 Study
Cardiovascular Aspects of Radiolog
Effects of nateglinide on myocardial microvascular reactivity in Type 2 diabetes mellitus - a randomized study using positron emission tomography
Targeting Glioblastoma Using a Novel Peptide Specific to a Deglycosylated Isoform of Brevican
Glioblastoma (GBM) is the most common and deadliest form of brain tumor and remains amongst the most difficult cancers to treat. Brevican (Bcan), a central nervous system (CNS)-specific extracellular matrix protein, is upregulated in high-grade glioma cells, including GBM. A Bcan isoform lacking most glycosylation, dg-Bcan, is found only in GBM tissues. Here, dg-Bcan is explored as a molecular target for GBM. In this study, a d-peptide library is screened to identify a small 8-amino acid dg-Bcan-Targeting Peptide (BTP) candidate, called BTP-7 that binds dg-Bcan with high affinity and specificity. BTP-7 is preferentially internalized by dg-Bcan-expressing patient-derived GBM cells. To demonstrate GBM targeting, BTP-7 is radiolabeled with 18F, a radioisotope of fluorine, and increased radiotracer accumulation is found in intracranial GBM established in mice using positron emission tomography (PET) imaging. dg-Bcan is an attractive molecular target for GBM, and BTP-7 represents a promising lead candidate for further development into novel imaging agents and targeted therapeutics